BLAINTRAMUSCULARSUSPENSION
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
3/8 — Basic
mRESVIA (respiratory syncytial virus vaccine) by Moderna. Approved for respiratory syncytial virus infection. First approved in 2024.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
mRESVIA is a messenger RNA (mRNA) vaccine developed by Moderna for the prevention of Respiratory Syncytial Virus (RSV) infection, approved by the FDA on May 31, 2024. It utilizes mRNA technology to stimulate immune response against RSV, offering a novel preventive approach to a respiratory virus that affects millions globally, particularly in vulnerable populations.
Growth
As a newly approved growth-stage vaccine with significant market potential, mRESVIA is expected to attract expanding commercial and R&D teams at Moderna over the next 24–36 months.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (14)
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
Started Oct 2025
25,000 enrolled
Respiratory Syncytial Virus (RSV)
A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Started Nov 2024
947 enrolled
RSV Immunisation
Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Started May 2024
2,226 enrolled
RSV Immunization
Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Started Feb 2024
6,300 enrolled
RSV Immunisation
Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)
Started Feb 2023
80 enrolled
Respiratory Syncytial Virus Infection
Worked on mRESVIA at Moderna? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.